Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.02.02
One of our clients published preclinical data on NASH on Oncotarget
One of our clients Kanazawa University has published the results of a study using STAMTM model on Oncotarget. Title: “Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet” The data of STAMTM mice is available in the Supplemental Figure 2 from the following link (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522259/bin/oncotarget-08-39978-s001.pdf)…
2025.02.02
Our clients published preclinical data on NASH on Molecular Cancer Research
One of our clients FDA-National Center for Toxicological Research (NCTR) has published the results of a study using STAMTM model on Molecular Cancer Research. Title: “Inhibition of the cell death pathway in non-alcoholic steatohepatitis (NASH)-related hepatocarcinogenesis is associated with histone H4 lysine 16 deacetylation“ The results of the study identified a reduction of global…
2025.02.02
Our clients published preclinical data on NASH-HCC on Oncotarget
One of our clients FDA-National Center for Toxicological Research (NCTR) has published the results of a study using STAMTM model on Oncotarget. Title: “MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis” By using STAMTM model (NASH-HCC model), they demonstrated that altered miRNA expression was associated with activation of major hepatocarcinogenesis-related pathway, including the TGF-b, Wnt/b-catenin,…
2025.02.02
Client Publication Announcement / European Radiology Experimental
We would like to introduce an update regarding a new article published by our client in European Radiology Experimental. Juntendo University Title: Free fatty acid-based low-impedance liver image: a characteristic appearance in nonalcoholic steatohepatitis (NASH) This paper examines whether the resistance (impedance) of free fatty acid (FFA) in the liver can be used…
2025.02.02
Experience in Evaluating Drug Efficacy in a Bleomycin-Induced IPF Model
Today, we would like to introduce the modalities and target molecules that we have experience in evaluating drug efficacy in our bleomycin-induced IPF model. SMC Laboratories has over 150 studies of experience in conducting IPF studies. As shown in the figure below, we have experience with test substances of various modalities, including small molecules,…
2025.02.01
Histopathological Analysis Service
We would like to introduce on our histopathological analysis service. Recently, we have received many inquiries from our clients regarding histopathological analysis, such as “We have conducted in vivo studies, but we are having trouble with histopathological analysis,” or ” We need analysis data evaluated by a third-party.” We have accumulated experience and…
2025.01.31
MASH model with high clinical correlation
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Around the world, the prevalence of NAFLD has now increased to 30%, and it is expected to continue to increase [Younossi Z et al., Hepatology. 2023]. One of the risks of NAFLD is its ability to progress to other…
2025.01.30
[ Consultations are increasing! ] The first step to accelerate MASH research
As you may already know, the United States Food and Drug Administration (FDA) announced the approval of Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals, as the first treatment for MASH. FDA approved first MASH treatment If you are developing a MASH treatment drug under these circumstances, by first contacting a specialized CRO, you will be…
2025.01.30
Introducing a preclinical model for Alzheimer’s disease
We would like to introduce you to an Alzheimer’s disease model. –About Alzheimer’s disease Alzheimer’s disease is a progressive neurodegenerative condition that currently has no cure and accounts for the majority of dementia cases. It is characterized by an accumulation of amyloid-beta, the main pathogen, in the brain and neuronal cell death due to…
2025.01.30
Introduction of Dextran Sulfate Sodium (DSS)-Induced Chronic Colitis Mouse Model
Today, we would like to briefly share with you a typical pathological mouse model of Inflammatory Bowel Disease (IBD), the Dextran Sodium Sulfate (DSS)-induced Chronic Colitis Model. The characteristics of the DSS-induced chronic colitis model are as follows: – Simple and reproducible disease induction method – Short disease induction period – Intestinal fibrosis such…
We can help you advance your research.